Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial

@article{Niskanen2012ComparisonOA,
  title={Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial},
  author={L. Niskanen and Lawrence A Leiter and E. Franek and J. Weng and T. Damci and M. Mu{\~n}oz-Torres and Jean-Paul Donnet and L. Endahl and T. V. Skj{\o}th and A. Vaag},
  journal={European Journal of Endocrinology},
  year={2012},
  volume={167},
  pages={287 - 294}
}
Objective Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of insulin degludec (70%) and insulin aspart (IAsp: 30%). Here, we compare the efficacy and safety of IDegAsp, an alternative IDegAsp formulation (AF: containing 45% IAsp), and biphasic IAsp 30 (BIAsp 30). Design Sixteen-week, open-label, randomised, treat-to-target trial. Methods Insulin-naive subjects with type 2 diabetes (18–75 years) and a HbA1c of 7–11% were randomised to twice-daily IDegAsp (n=61), AF (n=59… Expand
47 Citations
IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current status
  • 1
Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines
  • 1
Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
  • 22
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
Insulin Degludec in Type 1 Diabetes
  • 97
  • PDF
Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride.
  • P. Kann, T. Wascher, +6 authors M. Regulski
  • Medicine
  • Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • 2006
  • 113
...
1
2
3
...